AbbVie Inc. (NYSE:ABBV) finished Thursday with an addition of $2.7 to close at $143.01, an upside of 1.92 percent. An average of 6,939,940 shares of common stock have been traded in the last five days. There was a gain of $0.50 in the past week, and it reached a new high 55 times over the past 12 months. The last 20 days have seen an average of 5,175,875 shares traded, while the 50-day average volume stands at 5,352,034.
ABBV stock has increased by 2.87% in the last month. The company shares reached their 1-month lowest point of $134.10 on 09/01/22. With the stock rallying to its 52-week high on 04/08/22, shares of the company touched a low of $105.93 and a high of $175.91 in 52 weeks. It has reached a new high 32 times so far this year and achieved 5.62% or $7.61 in price. In spite of this, the price is down -18.70% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
123 days have passed since AbbVie Inc. (ABBV) last reported insider trading activity. SEVERINO MICHAEL, who is Vice Chairman, most recently acquired $79,801 shares at $150.90 per share on May 23. In this transaction, the insider spent $12,041,780. Vice Chairman, SEVERINO MICHAEL, disposed of 100,000 shares at a price of $154.04 on May 17. The insider now owns more than $15,404,400 worth of shares. Prior to that, EVP, Chief Strategy Officer Gosebruch Henry O went on to Sale 83,960 shares at $155.00 each on May 16. An amount of $13,013,800 was transacted.
AbbVie Inc. (ABBV) has a trailing price-to-earnings (P/E) ratio of 20.23. The stock’s beta is 0.67. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.36, the price-to-book (PB) ratio at 17.27, and the price-to-cash flow ratio at 19.93.
The company has a payout ratio of 76.40%. The company’s most recent quarterly dividend payment was $1.41 a share, without any change from last year. Its latest increase dividend $0.11 reported on Friday October 29 2021.
The quick ratio of AbbVie Inc. for the three months ended March 30 was 0.70, and the current ratio was 0.80, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 4.16 and a total debt to equity ratio of 4.98 for the quarter ending March 30. Its gross profit as reported stood at $38.75 billion compared to revenue of $56.2 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, AbbVie Inc.’s return on assets was 8.60%.
For the three-month period that ended March 30, AbbVie Inc. had $1.44 billion in cash and short-term investments compared to $61.0 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $924.0 million in the quarter, while revenues of $4.49 billion were grew 17.1%. The analyst consensus anticipated AbbVie Inc.’s latest quarter earnings to come in at $3.14 per share, but it turned out to be $3.16, a 0.60% surprise. For the quarter, EBITDA amounted to $5.35 billion. Shareholders own equity worth $1.77 billion.
From a technical analysis perspective, let’s take a brief look at AbbVie Inc. (ABBV) price momentum. RSI 9-day as of the close on 22 September was 57.96%, suggesting the stock is Neutral, with historical volatility in this time frame at 23.25%.
As of today, ABBV’s price is $142.36 +0.35% or $0.50 from its 5-day moving average. ABBV is currently trading +3.70% higher than its 20-day SMA and -2.63% lower than its 100-day SMA. However, the stock’s current price level is -6.01% below the SMA50 and +17.85% above the SMA200.
The stochastic %K and %D were 69.92% and 73.57%, respectively, and the average true range (ATR) was 3.14. With the 14-day stochastic at 80.65% and the average true range at 3.06, the RSI (14) stands at 54.96%. The stock has reached 0.07 on the 9-day MACD Oscillator while the 14-day reading was at 1.04.
Atlantic Equities downgraded AbbVie Inc. (NYSE: ABBV) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for AbbVie Inc. (ABBV) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell ABBV, while 8 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 13 others rate it as a “buy”.
What is ABBV’s price target for the next 12 months?
Analysts predict a range of price targets between $135.00 and $200.00, with a median target of $156.00. Taking a look at these predictions, the average price target given by analysts for AbbVie Inc. (ABBV) stock is $159.25.